Hepatocellular cancer, the most common form of primary liver cancer, is the fastest rising cause of cancer-related deaths in the United States. Texas has the highest incidence rates of HCC in the ...

A 39 year old nurse has recalled the four key symptoms that potentially saved her life, as she opened up about her critical liver cancer diagnosis.

Like many rare diseases, fibrolamellar hepatocellular carcinoma (FLC) mounts a ferocious attack against an ... a highly competitive initiative by Cancer Research (UK) and the National Cancer Institute ...

A new model has projected a substantial rise in the burden of metabolic dysfunction-associated steatotic liver disease in the ...

The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective ...

The US Food and Drug Administration has granted ... antagonist amezalpat (TPST-1120), for individuals with hepatocellular carcinoma (HCC). The ODD was awarded following positive outcomes from ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

A global comparative study on MDT practices in the management of hepatocellular carcinoma in high-income countries (HICs) and low- and middle-income countries (LMICs). This is an ASCO Meeting Abstract ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...